Skip to main content

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.

Publication ,  Journal Article
Gorse, GJ; Patel, GB; Newman, FK; Belshe, RB; Berman, PW; Gregory, TJ; Matthews, TJ
Published in: Clin Diagn Lab Immunol
July 1996

The ability of antibody induced by MN and IIIB recombinant gp120 (rgp120) human immunodeficiency virus type 1 (HIV-1) vaccines the bind to oligomeric native and monomeric recombinant HIV-1 envelope glycoproteins (rgp 120) was measured in 25 uninfected, healthy adult volunteers. A major focus was to evaluate the effect of simultaneous and sequential immunization with vaccines representing different strains of HIV-1 on the ability to broaden cross-reactivity of antibodies against these and other HIV-1 strains. A flow cytometric indirect immunofluorescence assay (FIFA) to detect vaccine-induced antibody to envelope glycoprotein expressed by infected and rgp120-coated target cells was used, MN rgp120 HIV-1 vaccine given alone and coadministered with IIIB rgp120 HIV-1 vaccine elicited antibody which bound to cells infected with HIV-1MN, HIV-IIIB, HIV-1RF, and HIV-1-SF2. The presence of envelope glycoprotein-binding antibody detected by FIFA correlated to a moderate degree with functional antibody against HIV-1MN and HIV-IIIB. Priming immunization with IIIB rgp120 HIV-1 vaccine followed by booster injections of MN rgp120 HIV-1 vaccine resulted in increased cross-reactive antibody binding to these and heterologous clade B HIV-1 strains infecting cells. MN rgp120 HIV-1 vaccine given alone was better able to induce cross-reactive antibody to cells infected with heterologous HIV-1 laboratory strains than was IIIB rgp120 HIV-1 vaccine given alone. The vaccines induced binding antibody to rgp120 possessing the amino acid sequence of a clade E HIV-1 strain as measured by enzyme-linked immunosorbent assay. Levels of antibody binding to cells infected with clade B HIV-1 and cells coated with monomeric rgp120 were greater than that induced by HIV-1IIIB-based gp160 vaccines in previous studies.

Duke Scholars

Published In

Clin Diagn Lab Immunol

DOI

ISSN

1071-412X

Publication Date

July 1996

Volume

3

Issue

4

Start / End Page

378 / 386

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • Protein Binding
  • Microbiology
  • Immunology
  • Immunization, Secondary
  • Immunization Schedule
  • Humans
  • HIV-1
  • HIV Envelope Protein gp120
  • HIV Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gorse, G. J., Patel, G. B., Newman, F. K., Belshe, R. B., Berman, P. W., Gregory, T. J., & Matthews, T. J. (1996). Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol, 3(4), 378–386. https://doi.org/10.1128/cdli.3.4.378-386.1996
Gorse, G. J., G. B. Patel, F. K. Newman, R. B. Belshe, P. W. Berman, T. J. Gregory, and T. J. Matthews. “Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.Clin Diagn Lab Immunol 3, no. 4 (July 1996): 378–86. https://doi.org/10.1128/cdli.3.4.378-386.1996.
Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, et al. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol. 1996 Jul;3(4):378–86.
Gorse, G. J., et al. “Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.Clin Diagn Lab Immunol, vol. 3, no. 4, July 1996, pp. 378–86. Pubmed, doi:10.1128/cdli.3.4.378-386.1996.
Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Clin Diagn Lab Immunol. 1996 Jul;3(4):378–386.

Published In

Clin Diagn Lab Immunol

DOI

ISSN

1071-412X

Publication Date

July 1996

Volume

3

Issue

4

Start / End Page

378 / 386

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • Protein Binding
  • Microbiology
  • Immunology
  • Immunization, Secondary
  • Immunization Schedule
  • Humans
  • HIV-1
  • HIV Envelope Protein gp120
  • HIV Antibodies